Here’s a snapshot of some MI start-up news that you may have missed over the last week: OtoSim Inc.'s medical training simulators, which teach otoscopy and otolargyngology skills in an…
Every six weeks, MaRS Innovation’s marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI’s activities or one of our start-up companies. You can read the original post on the MaRS blog.
Created in 2008, MaRS Innovation (MI) bridges the chasm between the early-stage technologies emerging from its 16 member institutions and successful startup companies and licensable technologies.
By offering early-stage funding in tandem with hands-on management, business development, mentorship and intellectual property protection strategy, MI acts as a commercialization agent for its members and researchers.
Earlier this year, the Networks of Centres of Excellence of Canada awarded MI $14.95 million to continue its mandate as a Centre of Excellence for Commercialization and Research (CECR), matched by $25 million from membership fees and private sector investments.
So what does that success mean for MI’s ability to serve the needs of academic entrepreneurs based in Toronto?
Happy New Year. Here’s a snapshot of some spin-off stories you may have missed over the holiday break:
OtoSim Inc. co-founder Dr. Vito Forte was selected as a recipient of the 2013 Canadian Association of Medical Educators (CAME) Certificate of Merit Award, which promotes medical education in Canadian medical schools while recognizing and rewarding faculty’s commitment to medical education. Dr. Forte will receive his certificate at the upcoming Canadian Conference on Medical Education (CCME) in Quebec City on Sunday, April 21, 2013. As co-founder of OtoSim Inc., Dr. Forte is actively involved in developing a pipeline of products including the OtoSim™, OtoSim™ Pneumatic Otoscopy Trainer and OptoSim™ (to be launched in early 2013).
Encycle Therapeutics, a MaRS Innovation spin-off company, was included in BioCentury‘s companies to watch within the macrocycle chemistry space.
The reference came in Chris Cain‘s article, “Maturing macrocycle chemistry drives explosion of biotech newcos, biopharma deals.”
Andrew Sinclair, CEO of OtoSim Inc. and a senior director at MaRS Innovation, describes some of the unexpected twists and turns OtoSim has weathered in bringing their product to market in…
Schwartz Reisman Innovation Campus, West Tower
108 College Street, Suite 530
Toronto, ON M5G 0C6
info@tiap.ca